Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 64. PMID: 27446916, PMCID: PMC4917534, DOI: 10.3389/fcell.2016.00064.Peer-Reviewed Original ResearchProstate cancerTumor initiating cellsHuman immune systemHumanized miceTherapeutic responsePersonalized therapeutic responseAdaptive T cellsPrimary prostate cancerPatient-derived organoidsPersonalized medicine approachPCa microenvironmentSelective engraftmentImmunotherapy approachesCommon malignancyCancer deathSpecific therapyImmune cellsDisease progressionCancer precision medicineCommon causeT cellsChimeric antigenPatient-specific therapiesMouse modelTherapy resistanceChapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerProstate cancerHormonal manipulationHormone-sensitive prostate cancerSecond-line hormonal manipulationsSecond-line hormonal therapySecond-line treatment optionAssociated response ratesInitial systemic therapySecondary hormonal manipulationsSecond-generation antiandrogensFirst-generation antiandrogensAntiandrogen withdrawalARN-509Hormonal therapyMainstay treatmentAbiraterone acetateAndrogen suppressionSystemic therapyAndrogen deprivationSuch patientsTreatment optionsTherapeutic responseDisease progressionResponse rate